NEW YORK, NY / ACCESSWIRE / February 16, 2016 / Vertex Pharmaceuticals Inc. (VRTX) was down by as much as 11.4% to $81.98 yesterday as investors were split on its earnings, reported after market close ...

Vertex Energy (VTNR) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one ...

Stifel: Analyst Paul Matteis adjusts the target price from $494 to $445, maintaining a hold rating. This mixed bag of ratings illustrates the cautious optimism surrounding Vertex Pharmaceuticals, as ...

Vertex Resource Group Ltd. ("Vertex" or the "Company") reports its financial and operational results for the third quarter ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at least as effective and costs only 50 cents a pill? They will if the generic ...

Loomis Sayles, an investment management company, released its “Growth Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). The Boston-based Big Biotech’s sodium channel inhibitor VX-993 failed to outpace ...

Thankfully, some companies can handle an inflationary environment and perform well throughout, while still registering the 12 ...

Treating pain has long been a challenge. Over-the-counter treatments often don’t do enough, while opioids block pain signals but can be extremely addictive. Vertex broke those barriers with Journavx, ...